The Food and Drug Administration on Friday scheduled three days of public meetings with its panel of independent vaccine experts for later this month, as the agency prepares to make high-profile decisions on whether to authorize emergency use of the Pfizer-BioNTech vaccine for children ages 5 to 11 and booster shots for adult recipients of the Moderna and Johnson & Johnson vaccines.
The F.D.A. typically issues its decisions within a few days of advisory committee meetings, during which members discuss safety and efficacy data. The timing of the upcoming meetings indicates that the agency intends to move quickly to decide whether to authorize both the booster and children’s shots.
The committee will meet on Oct. 14 and 15 to discuss booster doses, and is tentatively scheduled to discuss Pfizer’s pediatric vaccine on Oct. 26, the agency said.
“It’s critical that as many eligible individuals as possible get vaccinated as soon as possible,” Dr. Peter Marks, the agency’s top vaccine regulator, said in a statement.
He added that “the available data make clear that protection against symptomatic Covid-19 in certain populations begins to decrease over time, so it’s important to evaluate the information on the use of booster doses in various populations.”
The decision to have the committee discuss the evidence for Moderna and Johnson & Johnson booster shots two weeks before it does so for Pfizer’s children’s vaccine appears to reflect the F.D.A.’s priorities and the availability of data. But the agency’s decisions on those emergency use authorizations could come in quick succession.
Pfizer and BioNTech have yet to formally ask the F.D.A. to authorize emergency use of their vaccine for pediatric doses; they are expected to do so next week, according to people familiar with the companies’ plans. If regulators grant that request, it could help protect as many as 28 million children and ease the anxiety of parents across the nation. Dr. Scott Gottlieb,…